Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
Pfizer Pulls Plug On Weight Loss Pill Amid Liver Damage Fears
James Meyers
Apr 15, 2025 | 3:53 PM
We use cookies for various purposes including analytics and marketing. By continuing to use this service, you agree to use cookies by us and our third-party service providers as described in the Privacy Policy.